Acar J, Kulas A, Escudier B
Am Heart J. 1985 Mar;109(3 Pt 2):685-7. doi: 10.1016/0002-8703(85)90682-9.
In this report we describe the clinical and hemodynamic response of refractory cardiac failure to molsidomine. In the first part of the study the hemodynamic effects of a single oral dose of 2 or 4 mg of molsidomine were compared with placebo control in 23 patients. In the second phase the dose 8 to 24 mg/24 hours was used in nine patients with functional class III or IV symptoms over an average period of 28 months (range 7 to 42 months); a hemodynamic control study was performed. These data demonstrate that molsidomine has a hemodynamic effect on pulmonary artery pressure for 5 to 6 hours, that the peak effect is reached between 1 and 1 1/2 hours after oral intake, and that the clinical and hemodynamic benefits of molsidomine may be maintained in the long term in patients with particularly severe cardiac failure. The conditions of seven patients were clinically improved with treatment; significant reductions in mean right atrial, pulmonary artery, and pulmonary capillary pressures were observed.
在本报告中，我们描述了难治性心力衰竭对莫西赛明的临床和血流动力学反应。在研究的第一部分，23例患者口服2毫克或4毫克单剂量莫西赛明的血流动力学效应与安慰剂对照进行了比较。在第二阶段，9例心功能III或IV级症状患者在平均28个月（范围7至42个月）期间使用8至24毫克/24小时的剂量；进行了血流动力学对照研究。这些数据表明，莫西赛明对肺动脉压有5至6小时的血流动力学效应，口服后1至1.5小时达到峰值效应，并且在特别严重心力衰竭患者中，莫西赛明的临床和血流动力学益处可能长期维持。7例患者的病情经治疗后临床改善；观察到平均右心房、肺动脉和肺毛细血管压显著降低。
